Vir Biotechnology and Astellas Announce $1.71B Partnership, Accelerating Innovation in PSMA-Targeting TCEs
Another major milestone has reshaped the T-cell engager landscape. Vir Biotechnology and Astellas Pharma have entered a new global strategic partnership valued at $1.71 billion to advance Vir’s PSMA-targeting PROXTEN dual-masked T-cell engager program. The deal represents one of the most significant investments in the TCE space this year, reinforcing industry confidence in next-generation, tissue-selective immune-engaging modalities.
This collaboration is expected to accelerate the development of PROXTEN masked TCEs, designed to enable protease-specific activation within the tumor microenvironment, offering a promising path to improved safety profiles and reduced on-target, off-tumor toxicity.
Hear Directly From Vir at the 8th T Cell Engager Therapeutics Summit
As strategic collaborations and investment continue to accelerate across the TCE field, this year’s summit offers a timely opportunity to hear firsthand how leading developers are driving the next wave of precision-engineered T-cell engager therapies.
Explore the Brand-New Agenda
Hear the latest industry breakthroughs in T-Cell Engager development and gain exclusive modality and platform insights during our packed agenda.
Partner With Us
Position yourself as the go-to service provider of the rapidly progressing T-Cell Engager landscape to ensure your brand is at the heart of deals in this evolving space.
Join Biopharma Experts
Be part of the most critical conversations shaping the future of solid tumor and autoimmune therapy, where you can connect with like-minded experts across every stage of drug development.